<DOC>
	<DOCNO>NCT00487799</DOCNO>
	<brief_summary>To determine maximum tolerate dose ( MTD ) ularitide treatment subject hospitalize symptomatic acute decompensated heart failure ( ADHF ) .</brief_summary>
	<brief_title>A Study Ularitide Treatment Subjects With Acute Decompensated Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ularitide</mesh_term>
	<criteria>To consider eligible inclusion , subject must meet following criterion : Males females 18 year old . Unplanned hospitalization ADHF . Randomization occur soon possible presentation emergency department hospital ADHF 24 hour admission . Dyspnea rest assess subject 1 hour prior randomization . Subjects must ability interpret report selfassessed dyspnea . At least 1 follow 2 criterion : 1 . Prior medical history CHF ( eg , prior hospitalization CHF leave ventricular ejection fraction &lt; 40 % , determine transthoracic echocardiography time screen previously determine documented patient 's chart follow ) : Within previous 6 month subject unstable symptom , Within previous 12 month subject stable symptom . 2 . Clinical evidence ( screen ) heart failure , include abnormal jugular venous pressure ( JVP ) ( eg , &gt; 8 cm clavicle , assess 45°angle ) , rales crackle third base , 2+ low extremity edema . On optimal background therapy ADHF ( determine investigator ) ; subject require receive , minimum , least 1 hour oxygen supplementation least one dose IV furosemide minimum dose 40 mg last bolus deliver &gt; 2 hour study drug administration initiate ( another diuretic comparable dose ; eg , 2 mg bumetanide 20 mg torsemide , last bolus deliver &gt; 4 hour study drug administration initiate . If subject receive IV opiate , last dose must &gt; 3 hour administration study drug . Women childbearing potential must negative pregnancy test prior randomize study . Women men reproductive potential agree utilize effective contraception entire treatment period 1 month receive last dose ularitide placebo . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( accordance national local subject privacy regulation ) . Any subject ineligible study one follow criterion meet : Breathing rate &lt; 18 breath per minute ( measure 60 second ) . A systolic blood pressure ( SBP ) &lt; 110 mmHg &gt; 180 mmHg within hour randomization , SBP &lt; 120 mmHg subject receive IV inotropics vasodilator . A SBP &lt; 90 mmHg two successive measurement within 30 minute randomization . ( Subjects baseline IV inotropes vasodilator must stable dose ³3 hour prior randomization . ) BNP &lt; 400 pg/mL NT ? proBNP &lt; 1200 pg/mL anytime initial presentation hospital time randomization . Use IV contrast material within 48 hour infusion study drug . History central peripheral neurological ischemic disorder ( stroke , etc. ) . Active myocarditis , obstructive hypertrophic cardiomyopathy , congenital heart disease , restrictive cardiomyopathy , constrictive pericarditis , severe aortic stenosis , uncorrected primary valvular disease , significant obstructive valve disease . Acute decompensated heart failure associate endocrine ( eg , thyroid storm ) , metabolic , drugrelated toxicity . Elevation serum creatinine ? kinase myocardial band ( CK ? MB ) cardiac troponin ( Troponin I ) &gt; 2 time upper limit normal within 6 hour prior randomization . Active , ongoing myocardial ischemia , hospitalization acute myocardial infarction , administration thrombolytic therapy last 30 day prior randomization , , ECG abnormalities opinion investigator , suggestive active ischemic change . Percutaneous coronary intervention , coronary artery bypass graft surgery , cardiac surgery , major noncardiac surgery within 90 day prior randomization . Any cardiogenic shock ( SBP &lt; 90 mmHg sign symptom organ hypoperfusion ) initial presentation randomization . Any significant volume depletion severe electrolyte imbalance . Renal disorder creatinine clearance &lt; 30 mL/min , calculate CockcroftGault equation screening . Use phosphodiesterase type 5 ( PDE 5 ) inhibitor sildenafil within 72 hour prior randomization . Planned coronary revascularization procedure ( percutaneous coronary intervention coronary artery bypass graft ) current hospital admission . Use anticipate need invasive noninvasive mechanical circulatory ventilatory support . Anemia ( hemoglobin &lt; 10 mg/dL hematocrit &lt; 30 % ) . Vasculitis , active infective endocarditis , suspect infection include pneumonia sepsis . Body temperature ≥ 38º C. Significant acute chronic respiratory disorder ( eg , severe chronic obstructive pulmonary disease ) primary pulmonary hypertension baseline dyspnea may interfere ability interpret dyspnea assessment hemodynamic measurement . Terminal illness CHF expect survival &lt; 180 day . Previous exposure ularitide . Nesiritide treatment last 30 day prior randomization . Allergy natriuretic peptide . Participation clinical drug trial investigational device trial within 30 day prior randomization . Current drug abuse chronic alcoholism ( Investigator 's determination ) . Women pregnant breastfeeding . Women childbearing age urine pregnancy test determine pregnancy status within 24 hour prior randomization . Any condition , investigator 's opinion , make subject unsuitable study participation , include history repeat admission relate nonadherence prescribed medication . For subject concomitant invasive hemodynamic monitoring ( ie , pulmonary artery catheter monitoring ) : Baseline PCWP ≤ 20 mmHg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Acute Decompensated Heart Failure</keyword>
	<keyword>ADHF</keyword>
	<keyword>Heart Failure</keyword>
</DOC>